Phathom Pharmaceuticals Announces Appointment of Todd Branning as Chief Financial Officer
2020年7月13日 - 9:30PM
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late
clinical-stage biopharmaceutical company focused on developing and
commercializing novel treatments for gastrointestinal diseases,
today announced that it has appointed Todd Branning as Chief
Financial Officer. Interim CFO, David Socks, will
continue with the company as a strategic advisor and remain a
member of the Board of Directors.
Mr. Branning was most recently with Amneal Pharmaceuticals, Inc.
(NYSE: AMRX) where he served as Senior Vice President and Chief
Financial Officer. He brings a diverse global finance
background consisting of over 25 years of experience in corporate
finance and accounting, tax, financial planning and analysis, and
investor relations.
“I am delighted to welcome Todd to Phathom and to have him join
our executive leadership team. As we continue to grow our
organization and prepare for the potential commercialization of
vonoprazan, Todd’s expertise in finance and accounting will add
great value to our company,” said Terrie Curran, President and
Chief Executive Officer of Phathom. “I would also like to
thank David for his many contributions to Phathom and am excited
that we will continue to benefit from his expertise in business
development and his involvement in other key strategic areas.”
Mr. Branning has extensive finance experience in the
pharmaceutical industry. As SVP, CFO at Amneal
Pharmaceuticals, he helped to build, leverage, and optimize
infrastructure following the completion of a transformational
merger in May 2018. Prior to Amneal Pharmaceuticals, he
served as Senior Vice President, Chief Financial Officer for Teva
Pharmaceuticals' (NYSE: TEVA) Global Generic Medicines division.
Mr. Branning led the finance function and served on the
leadership team responsible for managing the day-to-day operations
of Teva's largest multi-billion dollar commercial unit. Prior
to joining Teva in 2016, he served as Vice President, Finance, for
Allergan plc. Mr. Branning has also served in financial
leadership roles at PricewaterhouseCoopers, PPG Industries, Inc.
and Merck & Co., Inc.
Mr. Branning holds an MBA degree from Carnegie Mellon University
and a BBA from the University of Miami. He is a Certified
Public Accountant and has completed a CFO certification program
from The Wharton School at the University of
Pennsylvania.
About VonoprazanVonoprazan is an oral
small molecule potassium-competitive acid blocker (P-CAB).
P-CABs are a novel class of medicines that block acid secretion in
the stomach. Vonoprazan has shown the potential to have rapid,
potent, and durable anti-secretory effects as a single agent in the
treatment of gastroesophageal reflux disease (GERD) and in
combination with antibiotics for the treatment of Helicobacter
pylori (H. pylori) infection. The U.S. Food and Drug Administration
(FDA) has designated vonoprazan as a qualified infectious disease
product (QIDP) and awarded Fast Track status for the treatment of
H. pylori infection in combination with both amoxicillin and
clarithromycin and with amoxicillin alone. Phathom in-licensed the
U.S., European, and Canadian rights to vonoprazan from Takeda,
which completed 18 Phase 3 trials for vonoprazan and received
marketing approval in 13 countries in Asia and Latin America.
About PhathomPhathom Pharmaceuticals is a
biopharmaceutical company focused on the development and
commercialization of novel treatments for gastrointestinal diseases
and disorders. Phathom has in-licensed the exclusive rights in the
United States, Europe, and Canada to vonoprazan, a novel potassium
competitive acid blocker (P-CAB) in late-stage development for the
treatment of acid-related disorders. For more information about
Phathom, visit the company’s website at www.phathompharma.com or
follow the Company on LinkedIn at
www.linkedin.com/company/phathompharma.
CONTACTSJoe Hand
1-877-742-8466info@phathompharma.com
Media Contact:Nick
Benedetto1-877-742-8466media@phathompharma.com
Investor Contact:Patti BankWestwicke
Partners415-513-1284patti.bank@westwicke.com
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 6 2024 まで 7 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 7 2023 まで 7 2024